Neil H Bander

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9403632/publications.pdf

Version: 2024-02-01

45 papers	4,577 citations	218592 26 h-index	254106 43 g-index
48 all docs	48 docs citations	48 times ranked	4809 citing authors

#	Article	IF	Citations
1	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	3.3	4
2	Pilot study of the diagnostic utility of 89 Zrâ€dfâ€IAB2M and 68 Gaâ€PSMAâ€11 PET imaging and multiparametric MRI in localized prostate cancer. Prostate, 2022, , .	1.2	8
3	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2642-2651.	3.3	26
4	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 630589.	1.3	26
5	Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. European Urology Focus, 2021, 7, 254-257.	1.6	14
6	Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. JAMA Oncology, 2021, 7, 1642.	3.4	3
7	Phase I trial of docetaxel plus lutetium-177-labeled antiâ€“prostateâ€specific membrane antigen monoclonal antibody J591 (177Luâ€J591) for metastatic castrationâ€resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e9-848.e16.	0.8	29
8	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	1.2	16
9	Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities). Reports of Practical Oncology and Radiotherapy, 2020, 25, 367-375.	0.3	14
10	Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part II on Urological Management). Reports of Practical Oncology and Radiotherapy, 2020, 25, 619-624.	0.3	7
11	Pilot Study of Hyperfractionated Dosing of Lutetium-177â€“Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2020, 25, 477-e895.	1.9	26
12	Phase 1/2 study of fractionated dose lutetiumâ€177â€“labeled antiâ€“prostateâ€specific membrane antigen monoclonal antibody J591 (¹⁷⁷Luâ€J591) for metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 2561-2569.	2.0	100
13	Meeting report from the Prostate Cancer Foundation PSMAâ€directed radionuclide scientific working group. Prostate, 2018, 78, 775-789.	1.2	35
14	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
15	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e15-530.e21.	0.8	38
16	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Research, 2016, 6, 7.	1.1	32
17	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285.	3.2	163
18	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research, 2015, 5, 28.	1.1	63

#	Article	IF	Citations
19	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy, 2014, 7, 2227.	1.0	36
20	89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2093-2105.	3.3	130
21	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature Communications, 2014, 5, 5383.	5.8	522
22	A Prospective Pilot Study of ⁸⁹ Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 2014, 191, 1439-1445.	0.2	73
23	In vitro Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells. Journal of Visualized Experiments, 2014, , .	0.2	1
24	Antibodyâ€“Drug Conjugate Target Selection: Critical Factors. Methods in Molecular Biology, 2013, 1045, 29-40.	0.4	43
25	Phase II Study of Lutetium-177â€“Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 5182-5191.	3.2	370
26	Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2013, 3, 214.	1.3	33
27	Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow. PLoS ONE, 2013, 8, e85143.	1.1	40
28	Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma Multiforme. Archives of Pathology and Laboratory Medicine, 2011, 135, 1486-1489.	1.2	101
29	Vascular Targeted Therapy With Antiâ€“Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors. Journal of Clinical Oncology, 2007, 25, 540-547.	0.8	208
30	Technology Insight: monoclonal antibody imaging of prostate cancer. Nature Reviews Urology, 2006, 3, 216-225.	1.4	119
31	Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 4591-4601.	0.8	468
32	Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. Journal of Nuclear Medicine, 2005, 46, 850-8.	2.8	68
33	Phase I Trial of Yttrium-90â€”Labeled Antiâ€”Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 2522-2531.	0.8	290
34	Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars in Oncology, 2003, 30, 667-676.	0.8	146
35	Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. Journal of Urology, 2003, 170, S84-8; discussion S88-9.	0.2	122
36	Na,K-ATPase Î²-Subunit Is Required for Epithelial Polarization, Suppression of Invasion, and Cell Motility. Molecular Biology of the Cell, 2001, 12, 279-295.	0.9	180

#	Article	IF	Citations
37	Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer and Metastasis Reviews, 1999, 18, 483-490.	2.7	61
38	The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. , 1999, 86, 492-497.		64
39	MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. , 1997, 33, 233-239.		85
40	CYTOTOXICITY OF GALLIUM NITRATE IN VITRO USING BLADDER CANCER CELLS. International Journal of Urology, 1995, 2, 288-294.	0.5	2
41	Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. International Journal of Cancer, 1993, 55, 96-101.	2.3	228
42	M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium. Journal of Urology, 1988, 139, 461-469.	0.2	517
43	Monoclonal antibodies in urologic oncology. Cancer, 1987, 60, 658-667.	2.0	22
44	Study of the Normal Human Kidney and Kidney Cancer with Monoclonal Antibodies. Uremia Investigation, 1984, 8, 263-273.	0.1	5
45	Re: In Vivo and in Vitro Effects of Xenogeneic Immune Ribonucleic Acid in Patients with Advanced Renal Cell Carcinoma: A Phase I Study, by Jerome P. Richie, Bosco S. Wang, Glenn D. Steele, Jr., Richard E. Wilson and John A. Mannick, J. Urol., 126: 24â€“28, 1981. Journal of Urology, 1982, 127, 783-783.	0.2	0